This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

CTI BioPharma 경영진

경영진 기준 점검 3/4

CTI BioPharma CEO는 Adam Craig, Mar2017 에 임명되었습니다 의 임기는 6.25 년입니다. 총 연간 보상은 $4.59M, 14.3% 급여 및 85.7% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $267.56K 가치에 해당하는 회사 주식의 0.022% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 6 년과 6.3 년입니다.

핵심 정보

Adam Craig

최고경영자

US$4.6m

총 보수

CEO 급여 비율	14.30%
CEO 재임 기간	6.3yrs
CEO 지분 보유율	0.02%
경영진 평균 재임 기간	6yrs
이사회 평균 재임 기간	6.3yrs

최근 경영진 업데이트

업데이트 없음

Recent updates

Seeking Alpha • Aug 17

CTI BioPharma: Reiterating Target Price Of $17 After Successful VONJO Launch

CTIC announced its 2Q 2022 results on 8 August. With booked revenues coming in at $12.3 million for the quarter, revenues were above Street expectations. In my view, the 26% share price decline since the results is a reaction to BVF Partners (a major equity holder of the company) selling shares. I view this decline as a major buying opportunity. I believe the market totally ignored the $8.2 million in accounts receivables reported by the company. The CFO’s repeated statements that CTIC has sufficient cash to meet its financial obligations through 2023 is a major clue that further dilution is not likely. I am maintaining my target price of $17. I will continue to hold CTIC until a buyout or my target is achieved in the next 1.5 to 3.5 years. Background As an update to my previous article on CTI BioPharma (CTIC), where I recommended this stock as a "Strong Buy" and a $17 price target, CTIC’s first complete quarter of sales in its history was greeted with enthusiasm by Wall Street analysts. Most analysts reiterated their “Buy” ratings and maintained or revised their price targets higher. While the launch of VONJO (CTIC's only approved drug for the treatment of adults with intermediate or high-risk post-polycythemia vera or post-essential thrombocythemia) was viewed as being successful by the street (and management), the $12.3 million in net sales reported by the company was only in line with Inrebic (BMY) sales in the first quarter after its launch in 4Q 2019. To a certain extent, traders were taking profits and viewed the $12.3 million revenue figure with disappointment, punishing the stock by -22.9% at one point on Tuesday, 9th April 2022, before the stock recovered to close -11.8% on that day. Since then, however, CTIC has lost about 26% of its value from its highs of $7.56 prior to the earnings release, coming back to about the level where I recommended the stock back on May 04, 2022. Another factor impacting the price dynamic was the fact that BVF Partners sold 8.5 million shares in the company on August 9, 2022 (according to BVF Partners' Form 4 filing). The market took this as a major equity holder selling stock and perhaps losing some faith in the growth prospects of the company. Why I am maintaining my DCF Valuation In my view, the market completely ignored the $8.2 million in Accounts Receivables reported by the company in 2Q.2022 (see pp. 4 of CTIC's 2Q.2022 10Q Filing). If we add this to the top line reported revenue figure, VONJO sales for the quarter would have been $20.5 million – or 70% higher than Inrebic sales at the same stage of Inrebic’s commercial launch. VONJO is off to a great start and confirms for me that VONJO is highly differentiated from Incyte Corporation's (INCY) JAKAFI. As I stated in my previous article, my own interviews with hematologists indicated that they have been waiting for VONJO to come to market for the 7,000 patients in the United States that suffer from severe thrombocytopenia (i.e., blood platelet counts under 50 x10^9 /L). Management’s repeated comments that there is a 60 / 40 split in hospital / community prescribers is also very bullish, as cancer drugs normally get acceptance in the hospital setting before a slow ramp up into the community setting. That is not the case for VONJO. While we may never know how many patient lives are impacted by CTIC (unless the company reveals it – which their CEO has refused to do in the past), we can model and benchmark this additional sales information to inform our unit economics going forward. At a wholesale price of $19,500, the $20.5 million in sales represents 350 prescriptions per month ($20.5 million / $19,500 / 3) in the quarter. It will be useful for us to track this number in order to understand CTIC’s market share gain over time. At 350 prescriptions (assuming 1 prescription per patient), CTIC’s market share of the 7,000 patients in the United States that suffer from severe thrombocytopenia now stands at 5%. Again, that is an excellent start. My expectation in my previous DCF model was a quick ramp-up to 1,750 patients, or a 25% market share by the end of 2022 (due to the unmet medical need). That is likely not going to happen. At a run rate of 350 patients per quarter, we are looking at 1,050 patients by the end of 2022 (a 15% market share). I do, however, think that in 2023, and beyond, VONJO is more than capable of taking a 30% market share in 2023, and a 50% market share in 2024, as CTIC continues to educate specialists on further positive trial data. See my slightly revised unit economics figures below: Table 1: CTIC’s Unit Economics Unit Economics 2022 2023 2024 2025 2026 2027 Old Model (May 2022) 1,750 2,333 3,500 3605 3,713 3,825 Old Model Revs ($ million) $209.6 $387.5 $604.6 $647.6 $693.7 $743.1 New Model(August 2022) 1,050 2,333 3,500 3,605 3,713 3,825 New Model Revs ($ million) $125.8 same same same same same Maintaining my Cost Forecast for CTIC While CTIC missed the street expectations on the bottom line by a penny, I was actually quite encouraged by management’s cost control. Total operating and non-operating expenses came in at $34.983 million, much lower than my run rate calculations of $53 million in my DCF model that you can see in my previous article. The $18 million difference was due partially to the fact that CTIC has not yet paid the $10.3 million owed to Takeda, opting instead to drag out this payment until March 15, 2023; and the $25 million payment to SBIO + low single-digit royalties to SBIO that continues to show in CTIC’s books under Intangible Assets, but will at some point move to the income statement. I am, therefore, maintaining my conservative cost forecasts for CTIC. BVF Sale was 18.8% of their overall holdings and likely motivated by fund dynamics The elephant in the room, of course, is the stock sale by BVF on August 9. While the retail comment boards were full of criticism about the BVF Partners’ stock sale, according to BVF’ Form 13F and Form 13D filings and CTIC's Form 8K filing, it looks like BVF sold 8.5 million shares out of its total holdings of 45.3 million shares of CTIC, or 18.8% of its holdings.

Seeking Alpha • Aug 08

CTI BioPharma GAAP EPS of -$0.21 misses by $0.01, revenue of $12.33M beats by $3.23M

CTI BioPharma press release (NASDAQ:CTIC): Q2 GAAP EPS of -$0.21 misses by $0.01. Revenue of $12.33M beats by $3.23M.

Seeking Alpha • Jul 19

CTI BioPharma: Approval Is Great, Now There's The Follow Through

CTI BioPharma's Pacritinib has been conditionally approved. It has critical differentiations with Incyte's Jakafi. While the potential is huge, cash and some data points are worrying signs. CTI BioPharma Corp. (CTIC) was granted accelerated approval of VONJO or pacritinib for the treatment of adults with myelofibrosis ("MF") with a platelet count below 50 times 10 to 9 per liter. This approval was based on the Phase III PERSIST-2 trial, a study that enrolled myelofibrosis patients with platelet counts less than or equal to 100 times 10 to 9 per liter, making it the only randomized controlled study specifically designed to recruit the cytopenic myelofibrosis population, that is patients with thrombocytopenia and anemia. Announcing the approval, the company CEO said: In the U.S., there are approximately 21,000 patients with myelofibrosis, two-thirds of which have cytopenias (thrombocytopenia or anemia), commonly resulting from the toxicity of other approved therapies. Severe thrombocytopenia, defined as a blood platelet count below 50 × 109/L, occurs in one-third of the overall myelofibrosis population, and has a particularly poor prognosis. With the approval of VONJO, we are excited to now be able to offer a new therapy that is specifically approved for patients with cytopenic myelofibrosis. We are fully funded for commercial launch, following our debt and royalty transactions with DRI, and we look forward to providing VONJO, the potential best-in-class therapy for cytopenic myelofibrosis patients, to patients within 10 days. Incyte's (INCY) Jakafi is also approved for MF patients, though it is approved for patients with a higher platelet count compared to VONJO. Jakafi earned $2.4bn last year, and while exact figures for the MF indication are not known to me, I am guessing that VONJO is looking at a huge market, running into billions of dollars. There are 21,000 MF patients in the U.S., and about a third of them have low platelets where no other therapy is approved. VONJO is priced at $19,500 per month, or $240,000 per year. That is an effective market of nearly $2bn in the U.S. alone. Jakafi's activity against both JAK1 and JAK2 versus pacritinib's focus on JAK2 only, mostly avoiding the problematic JAK1 pathway, gives it an edge. Like I discussed earlier, high-dose Jakafi at 20mg is effective but toxic, which is where VONJO has its advantage. As company management recently said: The physician -- the frustration of physicians, as we've said previously, is the dissatisfaction with low-dose rux. It's very common, particularly in the community practice because dose -- the dose has to be altered based on the toxicities seen, and it's -- it can be a complicated management scenario. What the feedback -- some of the feedback we've got from physicians has been the attractiveness of VONJO is that the drug can be given at full dose without the need for large numbers of dose modifications. CTIC was also lucky to be able to get VONJO included in NCCN guidelines, which is the largest network of comprehensive cancer treatment centers in the US. Inclusion here means wider propagation and a guarantee of higher sales because most oncologists in the U.S. - even elsewhere - look to the NCCN guidelines for latest updates on standard practices. Although the company still has to complete the PACIFICA trial (topline in 2025) for full approval, things are going well for VONJO so far. Last month, the company presented PERSIST 1 and 2 data at the European Hematology Association ((EHA)) 2022 Congress. According to Seeking Alpha: The analysis indicated a similar incidence of bleeding events as well as overall and fatal adverse events for pacritinib and ruxolitinib. Notably, the cardiac events were more common in patients who received pacritinib, CTIC said, attributing the difference mainly to higher rates of grade 1 peripheral edema on the therapy.

Seeking Alpha • Jul 07

CTI BioPharma initiated at outperform at Cowen on potential for Vonjo for myelofibrosis

Cowen has initiated CTI Biopharma (NASDAQ:CTIC) with an outperform rating citing the growth potential of Vonjo (pacritinib), which was approved in February for thrombocytopenic myelofibrosis. Shares are up 14% in Thursday afternoon trading. The firm has a $10 price target (~67% upside based on Wednesday's close). Analyst Boris Peaker said that one of the advantages of Vonjo over current treatments is that as a JAK2/IRAK1 inhibitor, it appears to be missing JAK inhibitor treatment-emergent thrombocytopenia and is also effective no matter the baseline platelet count. He added that Vonjo is approved for patients with very low platelet counts and the National Comprehensive Cancer Network guidelines call for the therapy's use in a second-line setting, both developments that support broader use. Incyte's (INCY) Jakafi (ruxolitinib) is a competitor to Vonjo, though it is approved for patients with a higher platelet count compared to Vonjo. Peaker is estimating $1B in peak sales, though the amount could be higher due to off-label use. Vonjo can achieve a 55% market share of U.S. patients by 2027, according to Seeking Alpha contributor Nizar Assanie.

Seeking Alpha • May 04

CEO 보수 분석

Adam Craig의 보수는 CTI BioPharma의 수익에 비해 어떻게 변했나요?
날짜	총 보수	급여	회사 수익
Mar 31 2023	n/a	n/a	-US$69m
Dec 31 2022	US$5m	US$657k	-US$93m
Sep 30 2022	n/a	n/a	-US$112m
Jun 30 2022	n/a	n/a	-US$121m
Mar 31 2022	n/a	n/a	-US$118m
Dec 31 2021	US$2m	US$633k	-US$98m
Sep 30 2021	n/a	n/a	-US$76m
Jun 30 2021	n/a	n/a	-US$63m
Mar 31 2021	n/a	n/a	-US$58m
Dec 31 2020	US$3m	US$615k	-US$52m
Sep 30 2020	n/a	n/a	-US$46m
Jun 30 2020	n/a	n/a	-US$44m
Mar 31 2020	n/a	n/a	-US$41m
Dec 31 2019	US$2m	US$595k	-US$40m
Sep 30 2019	n/a	n/a	-US$31m
Jun 30 2019	n/a	n/a	-US$36m
Mar 31 2019	n/a	n/a	-US$36m
Dec 31 2018	US$3m	US$564k	-US$29m
Sep 30 2018	n/a	n/a	-US$45m
Jun 30 2018	n/a	n/a	-US$42m
Mar 31 2018	n/a	n/a	-US$29m
Dec 31 2017	US$6m	US$434k	-US$45m

보상 대 시장: Adam의 총 보수(USD4.59M)는 US 시장에서 비슷한 규모 기업의 평균(USD3.70M) 수준입니다.

보상과 수익: Adam의 보상은 회사가 적자임에도 증가했습니다.

CEO

Adam Craig (57 yo)

6.3yrs

재임 기간

US$4,592,646

보수

Dr. Adam R. Craig, M.D., Ph D., M.B.A., has been the Chief Executive Officer, President and Director of CTI BioPharma Corp. since March 20, 2017 and serves its Interim Chief Medical Officer. Dr. Craig serv...

리더십 팀

이름	직위	재임 기간	보수	지분
Adam Craig	President	6.3yrs	US$4.59m	0.022% $ 267.6k
David Kirske	Executive VP	5.8yrs	US$1.47m	0.013% $ 155.7k
James Fong	Executive VP & Chief Commercial Officer	no data	US$597.30k	0.0027% $ 32.4k
Ed Bell	Senior Director of Investor Relations	15yrs	데이터 없음	데이터 없음
Bruce Bennett	Senior Vice President Global Pharmaceutical Operations	no data	데이터 없음	데이터 없음
John Volpone	Executive VP & Chief of Staff	no data	데이터 없음	데이터 없음
Jennifer Smith	Senior Vice President of Biometrics	4.6yrs	데이터 없음	데이터 없음

6.0yrs

평균 재임 기간

65yo

평균 나이

경험이 풍부한 관리: CTIC의 경영진은 노련하고 경험이 풍부합니다(평균 재임 6 년).

이사회 구성원

이름	직위	재임 기간	보수	지분
Adam Craig	President	6.3yrs	US$4.59m	0.022% $ 267.6k
Diane Parks	Independent Director	1.8yrs	US$301.12k	0% $ 0
Daniel Von Hoff	Chairman of Scientific Advisory Board	9.9yrs	데이터 없음	데이터 없음
Laurent Fischer	Independent Chairman of the Board	5.9yrs	US$352.12k	0% $ 0
David Parkinson	Independent Director	6yrs	US$317.62k	0% $ 0
Matthew Perry	Independent Director	7.4yrs	US$303.62k	0.033% $ 392.1k
Reed Tuckson	Independent Director	11.8yrs	US$319.12k	0.037% $ 442.1k
Michael Metzger	Independent Director	6.4yrs	US$330.62k	0% $ 0

6.3yrs

평균 재임 기간

65yo

평균 나이

경험이 풍부한 이사회: CTIC의 이사회는 경험이 있음으로 간주됩니다(평균 재임 6.3 년).

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2023/06/28 20:17
종가	2023/06/23 00:00
수익	2023/03/31
연간 수익	2022/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

CTI BioPharma Corp.는 16명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Kimberly Lee	Brean Capital Historical (Janney Montgomery)
Leah Rush Cann	Brookline Capital Markets
null null	BTIG